The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic
- PMID: 26058074
- DOI: 10.1016/j.ccell.2015.05.012
The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic
Abstract
The T790M mutation in EGFR accounts for approximately half of all lung cancer cases with acquired resistance to the current clinical EGFR tyrosine kinase inhibitors. In tyrosine kinase inhibitor-resistant lung tumors, rociletinib and AZD9291 are highly active when T790M is present and modestly active when T790M is absent.
Copyright © 2015 Elsevier Inc. All rights reserved.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
